Therefore, CYP1B1 could serve as a novel target for developing agents that inhibit CYP1B1 for treating the increased vascular reactivity, endothelial dysfunction, vascular hypertrophy, fibrosis, and ROS production associated with Ang II- and testosterone-dependent hypertension in males, but inhibitors of CYP1B1 could be detrimental in treating vascular changes associated with hypertension in females. This evidence concerns the gene AGT and Hypertension.